FOXO4-DRI

FOXO4-DRI is a synthetic senolytic peptide engineered to selectively eliminate senescent cells, commonly referred to as zombie cells, from aging tissues. Senescent cells are cells that have permanently exited the cell cycle in response to damage, oncogenic stress, or replicative exhaustion. Rather than dying through programmed cell death (apoptosis), they persist and secrete a destructive mixture of pro-inflammatory cytokines, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP). Accumulation of senescent cells is a major driver of age-related tissue dysfunction, chronic inflammation, and organ decline.

The peptide is designed using D-retro-inverso (DRI) topology, meaning it is built from D-amino acids arranged in a reversed sequence relative to the native FOXO4 protein. This configuration confers exceptional resistance to enzymatic degradation by proteases, giving FOXO4-DRI superior in vivo stability compared to peptides constructed from standard L-amino acids. The DRI designation is integral to the molecule's function, not merely a nomenclatural detail.

The mechanism of action targets the molecular survival circuit that keeps senescent cells alive. The transcription factor FOXO4 interacts with the tumor suppressor p53 within senescent cells, sequestering p53 in the nucleus and preventing it from triggering apoptosis. FOXO4-DRI competitively disrupts this FOXO4-p53 interaction. Once unbound, p53 translocates from the nucleus to the cytoplasm, where it activates the pro-apoptotic protein BAX, initiating the execution phase of apoptosis specifically in senescent cells. In vitro studies demonstrated an 11.73-fold difference in cytotoxicity between senescent and healthy control cells, confirming that healthy cells are largely spared.

Published animal studies have shown compelling results. In naturally aged and chemotherapy-induced aging mouse models, FOXO4-DRI treatment restored physical fitness, improved fur density and appearance, and improved renal function ^[1]. Studies on aged male mice showed that FOXO4-DRI improved the testicular microenvironment and partially restored testosterone secretion by eliminating senescent Leydig cells. A 2025 study in Nature Communications further characterized the structural basis of the FOXO4-p53 interaction and validated the peptide's mechanism using biophysical methods.